pelareorep

AXP000004.1 · Oncolytic virus

Platform
reovirus (serotype 3 Dearing, unmodified)
Originator
Oncolytics Biotech
Sponsor
Oncolytics Biotech

Names

NameTypeSource
pelareoreppreferred name, INNcurator, ncit
Reolysinbrandncit
PO-BB0209codencit
Reovirus Serotype 3 ambiguoussynonymncit

Virus

Role
Oncolytic
Family
Spinareoviridae
Virus
mammalian orthoreovirus (NCBI Taxonomy 351073)
Strain
type 3 Dearing
Replication
replicating
Modifications
none (wild-type isolate)
Route
intravenous, intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C60774
Wikidata
Q7313867
FDA UNII
S9J80L3D1U

Approvals

No regulatory approval recorded.

Clinical trials (35)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07446322FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal CancerRecruitingPhase 22026-04-302027-08-3060MSS Metastatic Colorectal Cancer; Ras-mutated Metastatic Colorectal Cancer; mCRC
NCT05514990Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH TrialActive not recruitingPhase 1/22022-10-072026-12-3110Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
NCT07280377A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabActive not recruitingPhase 1/22021-10-272027-07-30122Anal Cancer Metastatic; Pancreatic Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Unresectable Pancreatic Carcinoma
NCT05519059Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast CancerCompletedPhase 12021-10-112022-09-2915Advanced or Metastatic Breast Cancer
NCT04445844INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE StudyActive not recruitingPhase 22020-07-132025-06-3025Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Triple-negative Breast Cancer
NCT04215146A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 StudyActive not recruitingPhase 22020-06-102022-08-0148Breast Cancer Metastatic
NCT04102618A Window-of-opportunity Study of Pelareorep in Early Breast CancerTerminatedEarly phase 12019-03-292022-04-2026Breast Cancer
NCT03723915Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic CancerTerminatedPhase 22018-11-142019-12-1917Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
NCT03605719Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaCompletedPhase 12018-10-242022-10-1023Recurrent Plasma Cell Myeloma
NCT03282188REO13 Melanoma With of Without GM-CSFWithdrawnPhase 1/22017-102018-070Cancer of Skin; Melanoma
NCT03015922Viral Immunotherapy in Relapsed/Refractory Multiple MyelomaUnknownPhase 12017-06-052021-09-014Multiple Myeloma
NCT02723838Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the BladderWithdrawnPhase 12017-02-282017-09-300Muscle-invasive Transitional Cell Carcinoma of the Bladder
NCT02620423Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic AdenocarcinomaCompletedPhase 12015-122018-0311Pancreatic Adenocarcinoma
NCT02514382Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 12015-08-212022-04-1914Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
NCT02444546Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain TumorsCompletedPhase 12015-06-212018-07-136Childhood Astrocytoma; Childhood Atypical Teratoid/Rhabdoid Tumor; Diffuse Intrinsic Pontine Glioma; Glioma; Recurrent Childhood Anaplastic Oligodendroglioma; Recurrent Childhood Brain Neoplasm; Recurrent Childhood Glioblastoma; Recurrent Childhood Medulloblastoma; Recurrent Primitive Neuroectodermal Tumor; Refractory Brain Neoplasm
NCT02101944Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 12014-12-092021-05-0512Anemia; Recurrent Multiple Myeloma; Refractory Multiple Myeloma
NCT01656538A Study of Reolysin For Patients With Advanced/Metastatic Breast CancerCompletedPhase 22013-02-202016-11-1881Metastatic Breast Cancer
NCT01619813Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate CancerCompletedPhase 22012-12-142016-04-2685Prostate Cancer
NCT01708993Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage TherapyCompletedPhase 22012-12-102016-01-26166Non Small Cell Lung Cancer
NCT01622543Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal CancerCompletedPhase 22012-10-262017-01-18109Colorectal Cancer
NCT01533194Viral Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 12012-042015-0212Light Chain Deposition Disease; Refractory Plasma Cell Myeloma
NCT01199263Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerCompletedPhase 22010-12-062015-06-01108Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
NCT01280058Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic CancerCompletedPhase 22010-122016-01-1973Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma; Stage IV Pancreatic Cancer
NCT01274624Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal CancerCompletedPhase 12010-122018-0236KRAS Mutant Metastatic Colorectal Cancer
NCT01240538Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid TumorsCompletedPhase 12010-122014-0426Unspecified Childhood Solid Tumor, Protocol Specific
NCT01166542Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCompletedPhase 32010-062012-04167Carcinoma, Squamous Cell of the Head and Neck
NCT00998322A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic AdenocarcinomaCompletedPhase 22009-102013-1234Metastatic Pancreatic Adenocarcinoma
NCT00998192A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the LungCompletedPhase 22009-102013-0932Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
NCT00984464Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic MelanomaCompletedPhase 22009-092014-0214Metastatic Melanoma
NCT00861627Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR ActivationCompletedPhase 22009-032015-0937Carcinoma, Non-small Cell Lung
NCT00753038Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck CarcinomaCompletedPhase 22008-082011-0714Carcinoma, Squamous Cell of the Head and Neck
NCT00651157Viral Therapy in Treating Patients With Metastatic MelanomaCompletedPhase 22008-042011-1223Recurrent Melanoma; Stage IV Melanoma
NCT00602277Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum ChemotherapyCompletedPhase 12008-042016-0870Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
NCT00503295Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the LungCompletedPhase 22007-062011-0253Ewing Sarcoma Family Tumors; Fibrosarcoma; Leiomyosarcoma; Malignant Fibrous Histiocytoma; Osteosarcoma; Sarcoma, Synovial
NCT00528684Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant GliomasCompletedPhase 12006-072010-0418Malignant Glioma

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 39828738Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects.Journal of hematology & oncology2025cited by trial NCT02101944
PMID 40300087A Phase II Randomized Study of Paclitaxel Alone or Combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor-Positive Breast Cancer: The BRACELET-01/PrE0113 Study.Clinical cancer research : an official journal of the American Association for Cancer Research2025name in title: pelareorep
PMID 37443348Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).British journal of cancer2023cited by trial NCT03723915
PMID 37812476Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial.Clinical cancer research : an official journal of the American Association for Cancer Research2023cited by trial NCT02514382
PMID 33168658Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2021name in title: pelareorep
PMID 31694832Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.Clinical cancer research : an official journal of the American Association for Cancer Research2020name in title: pelareorep
PMID 32156785Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with KRAS-Mutated Colorectal Cancer.Molecular cancer therapeutics2020name in title: pelareorep
PMID 29027598A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.Breast cancer research and treatment2018cited by trial NCT01656538
PMID 29186319OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology2018cited by trial NCT01622543
PMID 29487723A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.Oncotarget2018cited by trial NCT01619813
PMID 29653857A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.Clinical colorectal cancer2018cited by trial NCT01622543
PMID 29748010Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.Lung cancer (Amsterdam, Netherlands)2018cited by trial NCT01708993
PMID 28289863A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.Cancer chemotherapy and pharmacology2017name in title: pelareorep
PMID 28756871Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.Gynecologic oncology2017name in title: Reolysin
PMID 26719427Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2016cited by trial NCT01280058
PMID 27039845Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.Molecular therapy : the journal of the American Society of Gene Therapy2016cited by trial NCT01280058
PMID 25728527A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.Pediatric blood & cancer2015name in title: Reolysin
PMID 26156229The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.BMC cancer2015name in title: Reolysin
PMID 25294913A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research2014name in title: Reolysin
PMID 26184025Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature.Clinical journal of gastroenterology2014name in abstract: Reolysin
PMID 22886613REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.Investigational new drugs2013name in title: Reolysin
PMID 22871663Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Molecular therapy : the journal of the American Society of Gene Therapy2012name in title: Reolysin
PMID 23121273Clinical trials involving the oncolytic virus, reovirus: ready for prime time?Expert review of clinical pharmacology2012name in abstract: Reolysin
PMID 19572105Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.Investigational new drugs2010name in title: Reolysin
PMID 20926400REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2010name in abstract: Reolysin

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 41741902Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.Journal of neuro-oncology2026name in abstract: Reolysin
PMID 41963749In Vivo Tracking Modalities for Oncolytic Reovirus: Principles, Clinical Applications, and Translational Integration.Molecular imaging and biology2026name in abstract: pelareorep
PMID 42105076Identification of reovirus reassortants with enhanced oncolytic activity in human fibrosarcoma cells.Virus genes2026name in abstract: pelareorep
PMID 42248646Operation oncolysis: Reoviruses in the theater of cancer war.Advances in cancer research2026name in abstract: pelareorep
PMID 42456895Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications.Annales pharmaceutiques francaises2026name in abstract: pelareorep
PMID 41228258The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.Cancers2025name in abstract: pelareorep
PMID 41463198Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions.Cancers2025name in abstract: pelareorep
PMID 38194598Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.Cancer immunology research2024name in abstract: pelareorep
PMID 36154608Gene Therapy Cargoes Based on Viral Vector Delivery.Current gene therapy2023name in abstract: Reolysin
PMID 36744961p38 Mitogen-Activated Protein Kinase Signaling Enhances Reovirus Replication by Facilitating Efficient Virus Entry, Capsid Uncoating, and Postuncoating Steps.Journal of virology2023name in abstract: pelareorep
PMID 36992407Viral Vectors in Gene Therapy: Where Do We Stand in 2023?Viruses2023name in abstract: Reolysin
PMID 37749907Oncolytic virotherapies for pediatric tumors.Expert opinion on biological therapy2023name in abstract: pelareorep
PMID 37829303Effectiveness and safety of pelareorep plus chemotherapy versus chemotherapy alone for advanced solid tumors: a meta-analysis.Frontiers in pharmacology2023name in title: pelareorep
PMID 34004331Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.Seminars in cancer biology2022name in abstract: pelareorep
PMID 35487285Clinical advances in oncolytic virotherapy for pediatric brain tumors.Pharmacology & therapeutics2022name in abstract: pelareorep
PMID 35796248GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers.Future oncology (London, England)2022name in title: pelareorep
PMID 35821679Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors.Neuro-oncology advances2022name in title: pelareorep
PMID 35836877Advances in the clinical development of oncolytic viruses.American journal of translational research2022name in abstract: pelareorep
PMID 33924556Oncolytic Virotherapy for Cancer: Clinical Experience.Biomedicines2021name in abstract: Reolysin
PMID 34332591Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis.Virology journal2021name in abstract: pelareorep
PMID 34372612Targeting JAK/STAT Signaling Antagonizes Resistance to Oncolytic Reovirus Therapy Driven by Prior Infection with HTLV-1 in Models of T-Cell Lymphoma.Viruses2021name in abstract: pelareorep
PMID 35035763Multimodal immune activation abilities and characteristics of reovirus.American journal of translational research2021name in abstract: pelareorep
PMID 35116288The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis.Translational cancer research2021name in abstract: Reolysin
PMID 33108458Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.Blood advances2020name in abstract: Reolysin
PMID 33142841Past, Present and Future of Oncolytic Reovirus.Cancers2020name in abstract: pelareorep
PMID 33426543Molecular Tools for Metastatic Colorectal Cancer Characterization.Journal of cellular immunology2020name in abstract: pelareorep
PMID 30462296Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.Japanese journal of clinical oncology2019name in abstract: pelareorep
PMID 30636617New Anti-Cancer Strategies in Testicular Germ Cell Tumors.Recent patents on anti-cancer drug discovery2019name in abstract: pelareorep
PMID 31679206Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy.Critical reviews in oncogenesis2019name in abstract: pelareorep
PMID 29799479A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.Cancers2018name in title: pelareorep
PMID 30261620The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.Cancers2018name in abstract: pelareorep
PMID 28812060Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.Molecular therapy oncolytics2017name in title: Reolysin
PMID 29156834Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas.Oncotarget2017name in abstract: pelareorep
PMID 26709987Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Cancer2016name in abstract: Reolysin
PMID 26809490Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.Molecular cancer therapeutics2016name in abstract: Reolysin
PMID 27019795Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.World journal of methodology2016name in abstract: Reolysin
PMID 27486853Oncolytic virus therapy: A new era of cancer treatment at dawn.Cancer science2016name in abstract: pelareorep
PMID 25341011Recent therapeutic advances in the treatment of colorectal cancer.Annual review of medicine2015name in abstract: Reolysin
PMID 25693885The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Investigational new drugs2015name in title: pelareorep
PMID 26513296Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.Oncotarget2015name in abstract: Reolysin
PMID 30190838Oncolytics Biotech® Inc.: REOLYSIN® for melanoma therapy.Melanoma management2015name in title: Reolysin
PMID 24419798Evaluation of homogeneity and genetic stability of REOLYSIN (pelareorep) by complete genome sequencing of reovirus after large scale production.Applied microbiology and biotechnology2014name in title: pelareorep
PMID 23824333Live viruses to treat cancer.Journal of the Royal Society of Medicine2013name in abstract: Reolysin
PMID 23868061Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.Cell death & disease2013name in title: Reolysin
PMID 24121993Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats.Investigational new drugs2013name in title: pelareorep
PMID 22002308Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.Oncogene2012name in abstract: Reolysin
PMID 21472724Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts.Cancer2011name in title: Reolysin
PMID 20024838AACR-NCI-EORTC--21st International Symposium. Molecular targets and cancer therapeutics--Part 1.IDrugs : the investigational drugs journal2010name in abstract: Reolysin
PMID 20801221The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.Methods (San Diego, Calif.)2010name in abstract: Reolysin
PMID 19527106Reovirus-based therapy for cancer.Expert opinion on biological therapy2009name in abstract: Reolysin
PMID 19806501Reovirus: Rationale and clinical trial update.Current opinion in molecular therapeutics2009name in abstract: Reolysin
PMID 18632239Rapid and reliable quantification of reovirus type 3 by high performance liquid chromatography during manufacturing of Reolysin.Journal of pharmaceutical and biomedical analysis2008name in title: Reolysin
PMID 18773127Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2008name in abstract: Reolysin
PMID 18806898Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2008name in abstract: Reolysin
PMID 19012507Reovirus therapy in cancer: has the orphan virus found a home?Expert opinion on investigational drugs2008name in abstract: Reolysin
PMID 17440629Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2007name in abstract: Reolysin
PMID 18473990Molecular targeting in pancreatic cancer.Reviews on recent clinical trials2007name in abstract: Reolysin
PMID 16774045Drug evaluation: Reolysin--wild-type reovirus as a cancer therapeutic.Current opinion in molecular therapeutics2006name in title: Reolysin
PMID 17167712Reovirus - possible therapy of cancer.Neoplasma2006name in abstract: Reolysin
PMID 15676074Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus).Health and quality of life outcomes2005name in title: Reolysin
PMID 14685303Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2003name in abstract: Reolysin
PMID 12113234Oncolytics Biotech releases REOLYSIN phase I clinical trial results.Expert review of anticancer therapy2002name in title: Reolysin
Unconfirmed matches (14)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 7745749Brain- and intestine-specific variants of reovirus serotype 3 strain dearing are selected during chronic infection of severe combined immunodeficient mice.Journal of virology1995name in title: Reovirus Serotype 3
PMID 8054525Reovirus serotype 3 infection in infants with extrahepatic biliary atresia or neonatal hepatitis.Journal of gastroenterology and hepatology1994name in title: Reovirus Serotype 3
PMID 8383165Tumor necrosis factor-alpha induction by reovirus serotype 3.Journal of leukocyte biology1993name in title: Reovirus Serotype 3
PMID 1870214The Lang strain of reovirus serotype 1 and the Dearing strain of reovirus serotype 3 differ in their sensitivities to beta interferon.Journal of virology1991name in title: Reovirus Serotype 3
PMID 2154608Passive immunity to fatal reovirus serotype 3-induced meningoencephalitis mediated by both secretory and transplacental factors in neonatal mice.Journal of virology1990name in title: Reovirus Serotype 3
PMID 2523177The sequences of reovirus serotype 3 genome segments M1 and M3 encoding the minor protein mu 2 and the major nonstructural protein mu NS, respectively.Virology1989name in title: Reovirus Serotype 3
PMID 2549167Antibody inhibits defined stages in the pathogenesis of reovirus serotype 3 infection of the central nervous system.The Journal of experimental medicine1989name in title: Reovirus Serotype 3
PMID 2718385The sequences of the S2 genome segments of reovirus serotype 3 and of the dsRNA-negative mutant ts447.Virology1989name in title: Reovirus Serotype 3
PMID 3267236The sequence of the reovirus serotype 3 L3 genome segment which encodes the major core protein lambda 1.Virology1988name in title: Reovirus Serotype 3
PMID 3553613Evidence that the sigma 1 protein of reovirus serotype 3 is a multimer.Journal of virology1987name in title: Reovirus Serotype 3
PMID 3799063Expression of the cloned S4 gene of reovirus serotype 3 in transformed eucaryotic cells: enrichment of the viral protein in the crude initiation factor fraction.Virus research1986name in title: Reovirus Serotype 3
PMID 6095208Molecular cloning and sequencing of the reovirus (serotype 3) S1 gene which encodes the viral cell attachment protein sigma 1.Nucleic acids research1984name in title: Reovirus Serotype 3
PMID 6546631Molecular cloning of the complete genome of reovirus serotype 3.Virology1984name in title: Reovirus Serotype 3
PMID 6927854Sequence at both termini of the 10 genes of reovirus serotype 3 (strain Dearing).Virology1982name in title: Reovirus Serotype 3

NIH grants

ProjectTitleOrganisationPIYearsLinked by
R50CA252135Improving Outcomes for Multiple Myeloma Patients through Novel Therapeutic InterventionsBECKMAN RESEARCH INSTITUTE/CITY OF HOPECASERTA, ENRICO2021–2025name in abstract: Reolysin
R01CA194742Reolysin-based combination therapy in relapsed multiple myelomaBECKMAN RESEARCH INSTITUTE/CITY OF HOPEPICHIORRI, FLAVIA2016–2021name in title: Reolysin
F30CA210334Balancing Efficacy and Toxicity of Intratumoral Reolysin for Diffuse Intrinsic Pontine Glioma (DIPG)MAYO CLINIC ROCHESTERSCHUELKE, MATTHEW2016–2020name in title: Reolysin
R01CA190789Endoplasmic reticulum stress and oncoviral therapyUNIVERSITY OF ARIZONANAWROCKI, STEFFAN T2015–2020name in abstract: Reolysin
P30CA013330Protocol - Specific Research SupportALBERT EINSTEIN COLLEGE OF MEDICINE, INCGOLDMAN, ISRAEL DAVID2013–2017name in abstract: Reolysin

Notes

Unmodified wild-type reovirus isolate; no transgenes.

How to cite

pelareorep (AXP000004.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000004.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.